Biocytogen attended Immuno-Oncology (IO) Summit 2018 congress in Boston, MA, Aug 28 - Aug 31. IO Summit has become the leading annual meeting focusing on the latest applied research. This conference covers immunomodulatory antibody engineering and emerging immuno-oncology targets, combination immunotherapy, preclinical and translational IO, predictive biomarkers and companion diagnostics, adoptive T cell therapy, oncolytic viruses and personalized cancer vaccines.
We were excited to learn about the projects and interests of booth attendees and were proud to introduce our animal models and preclinical service platform to attendees.
Taking advantage of our unique, highly-efficient gene editing platform, Biocytogen has successfully developed and validated a series of humanized immune checkpoint mouse models, including PD-1, PD-L1, CTLA4, TIM3, LAG3, OX40, 4-1BB, BTLA, GITR, CD27, CD28, CD40 and other immune modulators such as CD47, SIRPa and more. Double/triple humanized models have been established by crossing single humanized models. These models are powerful tools for preclinical in vivo efficacy studies for human antibodies discovery and combinational therapies.
We also have developed highly immune deficient mice (B-NDG) which lack T, B, and NK cells. This model is a great host for CDX, PDX. Meanwhile, human immune system can be easily reconstituted in B-NDG mice either by human PBMC or CD34+ HSC injection.
Biocytogen recently opened a new lab facility in Boston area (50C Audubon Road, Wakefield, MA) to better serve biopharma companies in US. Please feel free to contact email@example.com for further information.
Biocytogen is exhibiting at IO Summit congress